Table 5.
Cannabinoid medication (as the PRECIPITANT) affecting the metabolic enzyme levels/activity/drug effect of substrate medications (OBJECT) with a Narrow Therapeutic Index (NTI)
| Cannabinoid (as PRECIPITANT) | Affects the metabolism of the following SUBSTRATES with a Narrow Therapeutic Index (NTI) |
|---|---|
| Dronabinol (Marinol® and Syndros®) | CYP2C9 SUBSTRATES CYP3A4 SUBSTRATES |
|
| |
| Nabilone (Cesamet®) |
Nabilone is a (WEAK) INHIBITOR CYP2E1 SUBSTRATES CYP3A4 SUBSTRATES Nabilone is a (MODERATE) INHIBITOR CYP2C8 SUBSTRATES CYP2C9 SUBSTRATES |
|
| |
| CBD (Epidiolex®) |
CBD INHIBITS and INDUCES CYP1A2 SUBSTRATES CYP2B6 SUBSTRATES CBD INHIBITS CYP2C8 SUBSTRATES CYP2C9 SUBSTRATES CYP2C19 SENSITIVE SUBSTRATES UGT1A9 SUBSTRATES UGT2B7 SUBSTRATES |
|
| |
| Nabiximols (Sativex®) |
Nabiximols INHIBITS CYP2C8 SUBSTRATESa CYP3A4 SUBSTRATES UGT1A9 SUBSTRATES UGT2B7 SUBSTRATES Nabiximols INDUCES CYP1A2 SUBSTRATES CYP2B6 SUBSTRATES CYP3A4 SUBSTRATES |
CBD, cannabidiol; PI, prescribing information. a Listed in the CBD (Epidiolex®) PI.